Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | Delaware | 94-3171940 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | 400 Oyster Point Blvd., Suite ...

Table of Contents Table of Contents Titan Pharmaceuticals, Inc. Annual Report on Form 10-K For the Fiscal Year Ended December 31, 2021 Table of Contents | | | Page # | | --- | --- | --- | | PART I | | 3 | | Item 1. | Business | 4 | | Item 1A. | Risk Factors | 10 | | Item 1B. | Unresolved Staff Comments | 17 | | Item 2. | Properties | 17 | | Item 3. | Legal Proceedings | 17 | | Item 4. | Mine Safety Disclosures | 17 | | PART II | | 18 | | | Market for Registrant's Common Equity, Related Stockholder Matters a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number 001-13341 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-31719 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number 001-13341 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3171940 (S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021. OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number 001-13341 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3171940 (State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-13341 TITAN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 94-3171940 (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020. OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number 001-13341 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3171940 (State or other ...

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Q2 2020 Earnings Conference Call August 14, 2020 1:00 PM ET Company Participants Sunil Bhonsle - President and CEO Marc Rubin - Executive Chairman Kate DeVarney - Executive Vice President and Chief Scientific Officer Brian Crowley - Vice President of Finance Joe Schrei - Executive Director of Commercial Operations Mike Fritz - National Sales Director Jennifer Kiernan - IR Conference Call Participants John Vandermosten - Zacks Operator Thank you for holding and welco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020. OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number 001-13341 Titan Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3171940 (State or other juri ...

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Q1 2020 Results Conference Call May 15, 2020 12:00 PM ET Company Participants Sunil Bhonsle - President and CEO Dr. Marc Rubin - Executive Chairman Dr. Kate DeVarney - EVP and Chief Scientific Officer Brian Crowley - VP, Finance Jennifer Kiernan - Executive Assistant to CEO and Investor Communications Conference Call Participants John Vandermosten - Zacks Operator Good day, everybody, and thank you for holding. Welcome to the Titan Pharmaceuticals First Quarter 2020 ...